CD38 and acute lymphoblastic leukemia: Both IgG1 and IgA2 variants of daratumumab had marginal, if any, effects on ADCP or ADCC against T-ALL cells with low CD38 expression, such as the HSB-2 cell line with less than 12.4 ± 2.6 x103 SABC (Figure 1).